Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
about
Adult Stem Cell Responses to NanostimuliUsing biomaterials to study stem cell mechanotransduction, growth and differentiationToxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrA Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation.Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation.Extracellular vesicles as potential biomarkers of acute graft-vs.-host-disease.Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome.Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017.Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy
P2860
Q26801738-5FB76929-F951-4260-A5C3-902F27AC592FQ29030919-624A80F4-2F34-48F4-8804-0D00A344C8B8Q33402680-CD1D6037-7D64-4F3E-9A84-66F6B2A4FB40Q33783925-9BAFCCF1-991E-44B0-9099-0AF7ADD42C18Q34044024-27567525-73E0-4617-A247-2F81418EBAD7Q37088191-5A5CDD82-5C1C-4228-904E-6A8B1A5AAE77Q37284406-E9C85954-34B8-47A1-B83F-A49B07231D1AQ37627044-8B0D428D-B725-4CDD-87C7-A5F3C4E85618Q38635878-53202900-D3F3-4E9B-A8D1-CCE6E29E2347Q44984411-847692EF-0E6D-4F00-9BB3-CF93A4961A63Q46774796-84EA3084-F66B-4192-BE2C-BDD7C48AF11DQ47794767-6E9002BA-3008-4B63-8C87-D1EBA2BE2901Q55026920-D39E54F7-B686-467A-8BAF-2D762B3EB3B3Q58415992-8907A3DD-9513-4F9D-8CEA-2DF536168C0F
P2860
Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Nonmyeloablative unrelated don ...... r refractory multiple myeloma.
@ast
Nonmyeloablative unrelated don ...... r refractory multiple myeloma.
@en
type
label
Nonmyeloablative unrelated don ...... r refractory multiple myeloma.
@ast
Nonmyeloablative unrelated don ...... r refractory multiple myeloma.
@en
prefLabel
Nonmyeloablative unrelated don ...... r refractory multiple myeloma.
@ast
Nonmyeloablative unrelated don ...... r refractory multiple myeloma.
@en
P2093
P2860
P50
P1476
Nonmyeloablative unrelated don ...... r refractory multiple myeloma.
@en
P2093
Benedetto Bruno
Edward D Agura
George E Georges
Judith A Shizuru
Michael A Pulsipher
Michael B Maris
Mohamed L Sorror
Peter A McSweeney
Thoralf Lange
P2860
P304
P356
10.1016/J.BBMT.2006.11.011
P577
2007-02-01T00:00:00Z